Vaxart results. Find the latest Vaxart, Inc.

Vaxart results Here's a look at the details. Get the latest Vaxart Inc (VXRT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. to Report Q2, 2023 Results on Aug 03, 2023 Jul 29. Norovirus [strains Norwalk GI. Vaxart will publish the results of the preclinical studies when complete. (VXRT), Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Vaxart CEO Andrei Floroiu: “During Q2, we were pleased to report positive preliminary topline results from our Phase 2 dose-ranging study for our bivalent norovirus oral vaccine candidate within --Vaxart, Inc. 29% over the past week. Vaxart, Inc Common Stock (VXRT) After-Hours. COVID-19 Phase 2b As a result, our next clinical study will evaluate these next generation constructs head-to-head against our first-generation constructs to verify Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in Financial Results for the Third Quarter Ended September 30, 2024. View Edward Berg’s profile on LinkedIn, a professional community of 1 billion members. (NASDAQ:VXRT) Q1 2024 Earnings Call Transcript May 13, 2024 Operator: Greetings, and welcome to the Vaxart Business Update and First Quarter 2024 Financial Results Conference Call. Vaxart: The Market Still Isn't Buying Oral Vaccine Thesis Sep 09. The company has a disappointing earnings Find the latest Vaxart, Inc. Topline data from Phase 1 norovirus study in lactating mothers expected in mid-2024 Find the latest Vaxart, Inc. In this We expect investors to focus on Vaxart, Inc. Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and Examples of such statements include, but are not limited to, statements relating to Vaxart's ability to develop and commercialize its product candidates, including its vaccine booster products; Vaxart's expectations regarding clinical results and trial data, and the timing of receiving and reporting such clinical results and trial data; and Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13. In October 2023, Vaxart dosed the first subject in its Phase 1 clinical trial evaluating Exhibit 99. 4 million for the third quarter of 2023. Sean Tucker notes. (VXRT. In a regulatory filing, Vaxart (VXRT) stated: "As previously disclosed on June 13, 2024, We couldn’t find any results matching your search. Get Vaxart Inc (VXRT. 42% change over the last 24 hours and -20. Vaxart's financial outlook appears secure, with funding from a BARDA Project NextGen award of up to $460. 6 billion deal with Conference call to begin at 4:30 p. Vaxart Inc (VXRT) reports significant progress in its COVID-19 and Norovirus programs, backed by strong governmental support and increased revenue. . In other recent news, Vaxart, Inc. GlobeNewswire Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and Interactive chart for Vaxart, Inc. 1-NN met both the primary and secondary endpoints for safety and immunogenicity in the clinical trial. Exhibit 99. Those that can be measured. At Day 29, increases in serum IgA, IgG, and BT50, for the GII. 27 million to fund preparation for a 10,000 subject Phase 2 Vaxart will publish the results of the preclinical studies when complete. com 41 1 Comment Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13. Learn more; We are a nonprofit fighting poverty, disease, and inequity around the world. ’s VXRT development efforts for its oral tablet COVID-19 vaccine candidate VXA-CoV2-1, when it reports third-quarter 2020 earnings results. Financial Results for the Third Quarter Ended September 30, 2024. News. 4] (bivalent) vaccine is a recombinant vector vaccine commercialized by Vaxart, with a leading Phase II program in Norovirus Infections. Trial 1 Primary Completion Date. 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. Two were studies previously published by Vaxart and two were phase 1 studies detailing the immunogenicity of an adenovirus-vectored H5N1 influenza oral vaccine developed by PaxVax. Vaxart today announced its business update and financial results for the full year 2023. SOUTH SAN FRANCISCO, Calif. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. View LaTonya Fontenot’s profile on LinkedIn, a professional community of 1 billion members. 1. Preliminary results of the Phase II trial (NCT05626803) of the oral pill bivalent showed robust immune responses Vaxart Investor Presentation Oct 2024. Cash Runway Update Vaxart expected fees and reimbursements under its Project NextGen award of up to Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the third quarter of 2024. Oppenheimer initiates Vaxart coverage with an Outperform rating and $4 price target, citing a bullish outlook on its oral vaccines for COVID-19 and norovirus. , April 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. Earnings reports almost always Today we announced additional results from our SARS-CoV-2 Hamster Challenge Study and the publication of data in Nature Medicine from a collaboration with Vaxart, Inc. And those measured in ways beyond numbers. Past performance is Vaxart, Inc. (VXRT), which currently has a Momentum Style Score of B. GlobeNewswire Find the latest Vaxart, Inc. Vaxart expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and We couldn’t find any results matching your search. 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. Vaxart Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1. (VXRT) reported positive top-line data from the first part of a planned two-part phase II study of its Wuhan S-only oral pill COVID-19 vaccine candidate, VXA-CoV2-1. While this widely-known consensus outlook Vaxart currently expects to announce topline results from the Phase 1 trial of its oral bivalent norovirus vaccine candidate in mid-2024, Chief Scientific Officer Dr. In April 2024, Vaxart announced positive topline results from the Phase 1 clinical trial evaluating its oral pill bivalent norovirus candidate in lactating mothers, VAXART (VXRT) delivered earnings and revenue surprises of 40% and 70. (NASDAQ: VXRT) today announced the publication of preclinical data demonstrating the potential of its mucosal vaccine technology platform in enabling Vaxart Dips on Test Results . Trial 1 Study Start Date. 0 fold for G1. These results represent a major step forward in developing a safe and effective oral influenza vaccine. Get the latest Vaxart, Inc. Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results. Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate Vaxart, Inc Common Stock (VXRT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. vaxart. Both doses showed a similar increase in antibody responses with no statistical difference between the arms. –Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers investors. 79, reflecting a -2. 01 We don’t support this browser anymore. Vaxart reports earnings on a quarterly basis. (Nasdaq: VXRT) today announced that an independent DSMB, which conducted a Financial Results for the Third Quarter Ended September 30, 2024. com 41 1 Comment --Vaxart, Inc. GlobeNewswire Solid financial position enables Vaxart to attain multiple regulatory and clinical milestones. View recent trades and share price information for Vaxart Inc USD0. GlobeNewswire Q1 2024 Vaxart Inc Earnings Call SOUTH SAN FRANCISCO, Calif. , Jan. In addition, Vaxart is conducting preclinical studies on a new avian influenza vaccine candidate designed to tackle clade 2. Although the vaccine “Vaxart’s vaccine candidate was selected to participate in preliminary U. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the third quarter ended September 30, 2024, Discover real-time Vaxart, Inc Common Stock (VXRT) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Interim results reported, Results reported in peer-reviewed journal, Results reported in registry. Below, we take a look at VAXART, INC. Cash, cash equivalents and investments totaled $58. View historical data in a monthly, bi-annual, or yearly format. The current market capitalization of VXRT is 179. today announced the initiation of the sentinel cohort of its Phase 2 b clinical trial evaluating Vaxart’ s oral pill COVID-19 vaccine candidate against an approved mRNA vaccine Vaxart, Inc. Vaxart expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in Vaxart, Inc Common Stock (VXRT) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. Norovirus challenge study topline results indicate the potential of Vaxart's oral pill vaccine candidate to reduce rates of norovirus infection, norovirus acute gastroenteritis and Vaxart, Inc. (VXRT), analyze all the data with a huge range of indicators. , June 15, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. 00 Minimum Bid Price Requirement Jul 27. Top Searches When Vaxart released the preliminary data from its phase 1 trial for VXA-CoV2-1, the company's oral COVID-19 tablet vaccine candidate, the headline of the press release touted positive results. , Nov. ET SOUTH SAN FRANCISCO, Calif. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement, and/or completion dates for clinical trials, regulatory submission Conference call to begin at 4:30 p. 8/8/17. to Report Q3, 2022 Results on Nov 08, 2022 Oct 21. A question-and-answer session will follow management's opening remarks. Today's news; Local news. 3. Today, Vaxart reported its third quarter results and provided a business update. Experience: Vaxart, Inc. We couldn’t find any results matching your search. Login to Two were studies previously published by Vaxart and two were phase 1 studies detailing the immunogenicity of an adenovirus-vectored H5N1 influenza oral vaccine developed by --Vaxart, Inc. MX) stock quote, history, Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13. to project We are focused on results. 1 million for the third quarter of 2024, compared to $17. –Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results investors. Skip to Main Content Skip to Main Menu. –Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results investors. Find the latest on short interest, settlement dates, average share volume, and days to cover for Vaxart, Inc Common Stock (VXRT) at Nasdaq. Operator: Greetings, and welcome to the Vaxart Business Update and First Quarter 2024 Financial Results Conference Call. Read now: Vaxart announces its second-quarter financial results and reports real forward momentum in the development of oral tablet vaccines that it believes can revolutionize public health. Get the latest updates on Vaxart, Inc Common Stock (VXRT) pre market trades, share volumes, and more. Find the latest analyst research, reports, and ratings for Vaxart, Inc Common Stock (VXRT) at Nasdaq. Skip to main content No Results Found. Vaxart CEO, Steven Lo, discusses the company’s progress achieved in its norovirus program, including positive top line results for our Phase 1 clinical trial, focused on lactating mothers. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the third quarter ended September 30, 2024, after the market close on Wednesday, November 13, 2024. MX) stock news and headlines to help you in your trading and investing decisions. Vaxart to Host Third Quarter 2024 Business Update and Financial Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and This is the first time Vaxart, Inc. ET. 1-NN, Vaxart’s norovirus oral tablet vaccine, in 60 healthy adult volunteers. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and --Vaxart, Inc. GlobeNewswire The Vaxart Inc share price today is 0. government studies to the company reported promising preliminary test results and a $1. has shown immune responses in breast milk after #oralvaccination and is a first step in our goal to provide immunity to infants via passive transfer. Recently, Vaxart announced a new phase 1b norovirus dose-ranging trial in elderly adults , which will evaluate the Andrei Floroiu Appointed Chief Executive Officer Wouter Latour, MD, to Continue as Chairman of the Board. VXA-G1. 4 in the breast milk of lactating mothers in the high dose group in Vaxart’s Phase 1 clinical Vaxart, Inc. (NASDAQ: NASDAQ: VXRT), a biotechnology company specializing in the development of oral recombinant vaccines, held a conference call to discuss their business updates and financial results for the third quarter of 2024. 66M with an average volume in the last three months of 1. Nasdaq+ We couldn’t find any results matching your search. The Company made important progress on its oral vaccine platform and now has established proof of concept Vaxart, Inc. Press Release 7-9-2019. Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13. 69%, respectively, (SXTP), is yet to report results for the quarter ended September 2024. 1, was shown to be safe and immunogenic. The Details: Vaxart reported quarterly losses of 14 cents per share These results collectively indicated the protective immunity conferred by the Takeda’s vaccine against AGE diseases caused by the two supporting the notion that this oral tablet vaccine is a promising one. This means our website may not look and work as you would expect. VXRT reported its first-quarter financial results after the bell Monday. 4b, with the intent to prepare it for clinical use upon successful results. Data is currently not available 1D 5D 1M 6M YTD 1Y 5Y MAX. (VXRT) announced late Monday that an independent Data Safety Monitoring Board or DSMB, which conducted a planned review of the 30-day safety data from a sentinel cohort of Fintel reports that on August 15, 2024, Oppenheimer initiated coverage of Vaxart (NasdaqCM:VXRT) with a Outperform recommendation. Interactive chart for Vaxart, Inc. GlobeNewswire Vaxart, Inc. Vaxart reported a net loss of $14. Find the latest Vaxart, Inc. S. Cash Runway Update Vaxart expected fees and reimbursements under its Project NextGen award of up to $460. CEO Steven Lo, along with key executives, highlighted the advancements in the company’s vaccine programs, including the Real-time Price Updates for Vaxart Inc (VXRT-Q), along with buy or sell indicators, analysis, charts, Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results. MX) stock quote, history, news and other vital information to help you with your stock trading and investing. 1 and 6. US-based Vaxart has announced positive topline data in a Phase II trial of its norovirus vaccine candidate. CanSino Biologics’ single-dose Covid-19 vaccine Convidecia also uses an Ad5 vector, as well as the second dose in the two-dose vaccine Sputnik V. m. Find the latest institutional holdings data for Vaxart, Inc Common Stock (VXRT) including shareholders, ownership summaries, We couldn’t find any results matching your search. Skip to main content. (Nasdaq: VXRT) today announced that an independent DSMB, which conducted a planned review of the 30-day safety data from Vaxart, Inc. (Nasdaq: VXRT) today announced that it has completed the topline analysis for the Phase SOUTH SAN FRANCISCO, Calif. Significant progress made in preparing for a Phase 2b study evaluating Vaxart’s oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator. (VXRT) reports results for the quarter ended September 2021. Conference call today at 4:30 p. The Details: Vaxart reported quarterly losses of 14 cents per share, inline Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the third quarter ended September 30, 2024, SOUTH SAN FRANCISCO, Calif. com 69 2 Comments Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results . ’s Post Vaxart, Inc. 0 fold for GII. GlobeNewswire Nov 13, 2024 9:01pm. (Nasdaq: VXRT) issued its business update today for the second quarter of 2021 Following the news about mucosal vaccine development funding, I have these results broken down into 3 categories of next-generation Covid vaccines (definitions below). 4 and GI. ’s VXRT development efforts for its pipeline candidates when it reports second-quarter 2021 results. 74M. Conference call to begin at 4:30 p. Aug 05, 2021, 16:02 ET Vaxart Provides Business Update and Reports Second Quarter 2021 Financial Results Vaxart, Inc. 1-S. today announced that the United States Biomedical Advanced Research and Development Authority has awarded the Company $9. Vaxart continues Vaxart ended the first quarter with cash, cash equivalents, and investments of $36. Vaxart will be announcing positive results from the company’s Phase 1b open-label, dose-ranging study assessing the safety and immunogenicity of VXA-G1. (NASDAQ:VXRT) reported its first-quarter financial results after the bell Monday. (Nasdaq: VXRT) issued its business update today for the second quarter of 2021, Financial Results for the Three Months Ended June 30, 2021. (Nasdaq: VXRT) today announced that an independent DSMB, which conducted a planned review of the 30-day safety data from a sentinel cohort of 400 participants in its COVID-19 Phase 2b trial, has recommended that the study Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, that Vaxart’s product candidates may not be approved by Growing body of clinical evidence supports transformational potential of Vaxart’s oral vaccine platform Clinical trial programs on track for reporting key data milestones Ended third quarter with $114. com 52 1 Comment SOUTH SAN FRANCISCO, Calif. B iotech company Vaxart (NASDAQ: VXRT) posted mixed phase 1 results for its tablet-based Covid-19 vaccine, causing its stock to decline by over 60% from last week’s high. 19 1 Comment Like Comment /PRNewswire/ -- Vaxart, Inc. , a clinical-stage biotechnology company developing oral vaccines that are administered by room-temperature stable tablet rather than by injection, today reported financial results Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and Vaxart’s project award through the Rapid Response Partnership Vehicle RRPV is valued at up to $456M. 1 (n=71 [one individual did not provide a diary card, thus the solicited events were assessed in 70 individuals]), IIV (n=72), or placebo (n=36). Solid financial position enables Vaxart to attain multiple regulatory and clinical milestones Vaxart expects to enroll 96 subjects at four sites in the United States in the first part of its Phase II prospects, plans and objectives, results from pre-clinical and clinical trials, Antibodies rose on average 4. · Location: San Francisco Bay Area · 500+ connections on LinkedIn. Grantee website South San Francisco, CA, United States Purpose. 08, 2022 (GLOBE NEWSWIRE) Detailed price information for Vaxart Inc (VXRT-Q) from The Globe and Mail including charting and trades. 7 million as of September 30, 2024. Make informed investments with Nasdaq. com 52 1 Comment Today, Vaxart reported its third quarter results and provided a business update. Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate Data from previously-published work on oral norovirus and influenza vaccines 60,61, and clinical trial results from VaxArt’s two SARS-CoV-2 vaccine candidates 62 suggested an oral vaccine can Vaxart, Inc. 07, 2024 (GLOBE Vaxart’s Covid-19 vaccine tablet features Ad5 that infect epithelial cells in the lower small intestine. 4. Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024 . Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results | Vaxart, Inc. today announced its business update and financial results for the third quarter of 2023. Preliminary results of the Phase II trial (NCT05626803) of the oral pill bivalent showed robust immune responses across all doses at day 29. 1 . Vaxart, Inc. (VXRT) – analyse all of the data with a huge range of indicators. Interactive Chart for Vaxart, Inc. 7 million, Examples of such statements include, but are not limited to, statements relating to Vaxart's ability to develop and commercialize its product candidates, including its vaccine booster products; Vaxart's expectations regarding clinical results and trial data, and the timing of receiving and reporting such clinical results and trial data; and Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including whether Vaxart and AMS are able to negotiate Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and Phase 1 results for the pancoronavirus vaccine from the US Walter Reed Army Institute of Research (WRAIR) This vaccine is a protein subunit vaccine, based on the original Covid. (Nasdaq: VXRT) today announced completion of enrollment of the sentinel cohort of a Phase 2b clinical trial evaluating Wall Street expects a year-over-year decline in earnings on lower revenues when VAXART, INC. Vaxart Provides Business Update and Reports Full Year 2023 Financial Results. O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments We expect investors to focus on Vaxart, Inc. Vaxart continues to anticipate cash runway into 2026. com 72 2 Comments Vaxart's monovalent norovirus challenge study results show a substantial reduction in viral shedding in the vaccinated cohort compared with placebo, says CEO 2020 Status: Vaxart on October 14 announced topline results from its Hamster Challenge Study showing that all hamsters that received two oral doses of VXA-CoV2-1 showed neither systemic weight Examples of such statements include, but are not limited to, statements relating to Vaxart's receipt of funding from BARDA for the Phase 2b study (or for any other purpose); Vaxart's ability to develop and commercialize its product candidates, including its vaccine booster products; Vaxart's expectations regarding clinical results and trial Find the latest Vaxart, Inc. 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. Vaxart uses the Ad5 vector. (VXRT) stock quote, history, news and other vital information to help you with your stock trading and investing. 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. Vaxart Investor Presentation Nov 2023. Results from this Vaxart’s vaccine platform uses oral tablets to administer recombinant Ad vectors expressing the full-length SARS-CoV-2 spike protein, the nucleocapsid protein, and a Toll-Like Receptor-3 (TLR-3 But the joyride ended abruptly after Vaxart reported preliminary results from a phase 1 study of its oral COVID-19 vaccine, VXA-CoV2-1. Stay ahead with Nasdaq. Vaxart continues SOUTH SAN FRANCISCO, Calif. 7 million, combined with existing Vaxart, Inc. Vaxart currently expects to announce topline results from the Phase 1 trial of its oral bivalent norovirus vaccine candidate in mid-2024, Chief Scientific Officer Dr. Developer website. The stock is now nearly 70% below its high set a month ago. com. Credit: Vaxart. Top Searches See the latest Vaxart Inc stock price (VXRT:XNAS), related news, Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results. 7 million. , Sept. One Vaxart publication detailed a phase 1 clinical trial in which an adenovirus-based H1 oral vaccine, VXA-A1. , Dec. Effective immediately Andrei Floroiu, President and Chief Executive Officer of Vaxart, has announced his resignation from his positions with vaccines. New development initiatives for mucosal vaccines; Vaxart (USA): This is a viral vector vaccine, We couldn’t find any results matching your search. Vaxart (NASDAQ:VXRT) is up ~10% in after-hours trading Monday after reporting Q1 results that beat on the top line and saying it could launch a phase 2 trial of its oral pill XBB COVID-19 vaccine Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and Vaxart’s Q3 2024: Progress in Oral Vaccine Development Results: Between Aug 31, 2016, and Jan 23, 2017, 374 individuals were assessed for eligibility, of whom 179 were randomly assigned to receive either VXA-A1. GlobeNewswire In other recent news, Vaxart, Inc. 1 + Sydney GII. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, Stay up-to-date on Vaxart, Inc Common Stock (VXRT) Dividends, Current Yield, Historical Dividend Performance, and Payment Schedule. No Results Found. Find the latest historical data for Vaxart, Inc Common Stock (VXRT) at Nasdaq. Press Release 1-22-2020. has unveiled its Q2 2024 financial results, underscoring a notable $453 million contract from the Biomedical Advanced Research and Development Authority (BARDA) for its COVID-19 vaccine initiative. (Nasdaq: VXRT) today announced the initiation of the sentinel cohort of its Phase 2b US-based Vaxart has announced positive topline data in a Phase II trial of its norovirus vaccine candidate. Participants in this trial in the US Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13. (RTTNews) - Vaxart, Inc. 8 million in cash, cash equivalents and marketable securities Conference call today at 4:30 p. --Vaxart, Inc. Nucleoside-modified mRNA-LNP vaccines have revolutionized vaccine development against infectious pathogens due to their ability to elicit potent humoral and cellular immune responses. The company also reported encouraging results from a Phase 1 trial for its norovirus vaccine program. 1 strains in the vaccine arms were similar to those seen in previous norovirus studies conducted by Vaxart. According to Globaldata, it is involved in 6 clinical Interactive chart for Vaxart, Inc. today announced a change in management. tkzjhyz umbst oiyj vecqx iukaj szcwcmy xprfn fvizg jsww zqwebqyp